Selecting the Appropriate Patients and Monitoring Responses to CAR T-Cell Therapy in LBCL

The CRL did not identify any deficiencies related to the manufacturing, efficacy, or safety outlined in the BLA, and no new clinical trials were requested.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

The FDA has approved acalabrutinib in previously untreated MCL based on results from the phase 3 ECHO trial.

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Here are 3 things you should know about immunotherapy in diffuse large B-cell lymphoma.

Results from the CLOVER WaM trial saw a clinical benefit rate of 98.2% in patients with Waldenström Macroglobulinemia treated with Iopofosine I 131.